Artiva Biotherapeutics, Inc. (ARTV) Stock Forecast
ARTV analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.83 / 5 from 6 analysts
- Price target
- $35.80 average of analyst targets
- Upside to target
- +512.0% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.54
- 52-week range
- $3.07 – $13.39
ARTV analyst ratings
6 analystsNumber of analysts at each rating.
ARTV price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ARTV earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.53 | −$0.56 | −$0.47 | −$0.88 | +39.3% | 5 |
| Current fiscal year (2026) | −$2.51 | −$2.63 | −$2.30 | −$3.43 | +26.8% | 5 |
| Next fiscal year (2027) | −$2.61 | −$3.31 | −$2.25 | −$2.51 | −3.9% | 5 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ARTV revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 6 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 6 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 6 |
ARTV EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ARTV EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.52 | −$0.52 | −$0.53 | −$0.53 | −$0.53 | +2.2% | 0 up · 0 down |
| Current fiscal year (2026) | −$2.43 | −$2.43 | −$2.51 | −$2.51 | −$2.51 | +3.2% | 1 up · 0 down |
| Next fiscal year (2027) | −$2.81 | −$2.81 | −$2.61 | −$2.61 | −$2.61 | −7.4% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ARTV earnings surprises
Reported EPS vs the consensus estimate for the last 10 quarters; ARTV beat in 1 of 10.
What analysts expect from ARTV
6 analysts cover Artiva Biotherapeutics; their consensus rating is strong buy (4.83 on a 1–5 scale, where 5 is a strong buy). The average price target is $35.80, 512.0% above the latest close of $5.85. Analysts expect earnings of −$2.51 per share for 2026, +26.8% from a year earlier. For 2027 the average estimate is −$2.61 per share. Artiva Biotherapeutics beat the EPS estimate in 1 of the last 10 quarters.
Related: ARTV income statement, ARTV key metrics, ARTV chart. See the ARTV stock overview for the latest quote and news.
ARTV forecast FAQ
What is Artiva Biotherapeutics's price target?
The average analyst price target for Artiva Biotherapeutics is $35.80, 512.0% above the latest close of $5.85.
Is Artiva Biotherapeutics a buy, hold or sell?
Of 6 analysts covering Artiva Biotherapeutics, 5 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Artiva Biotherapeutics's EPS forecast?
Analysts forecast −$2.51 per share for 2026 (range −$2.63 to −$2.30); for 2027 the estimate is −$2.61.
When does Artiva Biotherapeutics report earnings?
Artiva Biotherapeutics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026; the EPS estimate is $-0.54.
Does Artiva Biotherapeutics usually beat earnings estimates?
Artiva Biotherapeutics reported EPS at or above the analyst estimate in 1 of the last 10 quarters.